Cellectar Biosciences (CLRB) Set to Announce Earnings on Wednesday

Cellectar Biosciences (NASDAQ:CLRBGet Free Report) is scheduled to post its quarterly earnings results before the market opens on Wednesday, March 27th. Analysts expect Cellectar Biosciences to post earnings of ($0.58) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Cellectar Biosciences Trading Up 4.7 %

Shares of CLRB stock opened at $4.05 on Monday. The company’s fifty day simple moving average is $3.67 and its 200-day simple moving average is $2.92. Cellectar Biosciences has a 52 week low of $1.30 and a 52 week high of $4.45. The company has a market cap of $49.77 million, a PE ratio of -1.25 and a beta of 0.93.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CLRB. Nantahala Capital Management LLC acquired a new position in shares of Cellectar Biosciences in the 4th quarter valued at about $3,741,000. Vanguard Group Inc. raised its position in shares of Cellectar Biosciences by 174.6% during the 4th quarter. Vanguard Group Inc. now owns 482,890 shares of the biopharmaceutical company’s stock worth $1,338,000 after buying an additional 307,006 shares in the last quarter. Worth Venture Partners LLC raised its position in shares of Cellectar Biosciences by 122.8% during the 1st quarter. Worth Venture Partners LLC now owns 458,245 shares of the biopharmaceutical company’s stock worth $315,000 after buying an additional 252,570 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Cellectar Biosciences during the 4th quarter worth about $191,000. Finally, Renaissance Technologies LLC raised its position in shares of Cellectar Biosciences by 31.3% during the 2nd quarter. Renaissance Technologies LLC now owns 166,500 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 39,700 shares in the last quarter. 16.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. StockNews.com raised shares of Cellectar Biosciences to a “sell” rating in a research note on Thursday, December 28th. Roth Mkm reaffirmed a “buy” rating and set a $20.00 price target on shares of Cellectar Biosciences in a report on Monday, March 4th.

Get Our Latest Stock Analysis on Cellectar Biosciences

Cellectar Biosciences Company Profile

(Get Free Report)

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer.

Featured Articles

Earnings History for Cellectar Biosciences (NASDAQ:CLRB)

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.